What's happening in and around the Park? Here is an update from the team at the Illinois Science + Technology Park. |
|
NorthShore, Edward Elmhurst Merger |
|
NorthShore University Health System and Edward-Elmhurst Health are planning to merge and create a nine-hospital health care operation with the second-largest physician group in the state.
NorthShore operates six hospitals: Northwest Community Hospital in Arlington Heights, Glenbrook Hospital in Glenview, Evanston Hospital, Highland Park Hospital, Skokie Hospital and Swedish Hospital in Chicago. Edward-Elmhurst runs Edward Hospital and Linden Oaks Behavioral Health in Naperville as well as Elmhurst Hospital.
Combined, the two systems would employee more than 25,000 workers, have a network of roughly 6,000 physician partners and offer more than 300 sites of care throughout the Chicago area.
|
|
The nine hospitals account for nearly 2,400 hospital beds in the suburbs and the north side of Chicago.
"We're incredibly excited what this means to our patients and people," said J.P. Gallagher, NorthShore's CEO. "This is a doubling down on making community based care stronger and more vibrant for many, many years to come."
|
|
NuMat Technologies - Sumitomo Partnership |
|
NuMat Technologies announced a partnership with Sumitomo Chemical Co., Ltd. to develop sustainable chemical separation technologies that can efficiently and dramatically reduce the carbon emissions and carbon footprint required to produce critical chemicals used in key sectors of the global economy.
Traditional chemical separation processes require substantial energy to operate, and significant capital investment. The drive for energy-efficient and cost-effective alternatives is of critical importance to achieve carbon emission reduction objectives outlined in the Paris Climate Agreement. Through this collaboration, both companies will apply their world-class expertise in advanced separation and precision-engineered materials to develop novel solutions that can displace incumbent technologies longer-term, while working towards near-term commercial targets.
|
|
"We're proud to partner with Sumitomo Chemical in unleashing the potential of Programmable Chemistries to address complex sustainability challenges in the chemicals industry," stated Ben Hernandez, Founder and Chief Executive Officer at NuMat Technologies. "Sumitomo Chemical and NuMat are joined by a shared mission to use chemistry in solving the problems that matter, and I’m excited at the innovation opportunities our collaboration can unlock."" |
|
Space Now Available @ISTP |
|
There is laboratory and office space available in 8045 Lamon. Suites, ranging from approximately 10,000 sq. ft. to over 50,000 sq. ft., are ready now. Options appropriately address your access and security concerns. Interested? Click here!
8045 Lamon (Research to Commercialization)
- 4 story, 163,000 square feet
- Gold LEED rated “green” facility
- Conference Center and Auditorium
- Areas for meetings, collaboration and socialization
Design your customized lab & office facilities at 8030 Lamon. (Flexible Options for Development)
- Flexible build to suit options
- Up to 200,000 square feet of office and development space
|
|
“The Illinois Science + Technology Park is a significant contributor to Skokie’s employment base and economic growth,” said Skokie Mayor George Van Dusen. “The park continues to grow and contribute to Skokie’s economy while also providing economic stimulus for the state and Midwest region.” |
|
Northwestern Research Funding- Record $893M |
|
“The remarkable depth and breadth of Northwestern research continues to make a huge positive impact, transforming entire fields and strengthening society,” Milan Mrksich, vice president for research. said. “As we continue to go from strength to strength — including important investments in our entrepreneurial and innovation ecosystem to increase translation — we will enhance our already superb research enterprise to keep elevating Northwestern’s reputation as a premier destination for the best scholars, scientists and students in the world.”
|
|
Northwestern University’s research enterprise once again demonstrated strong performance, with annual sponsored funds reaching a new record high of $893.4 million for the fiscal year that closed Aug. 31.
This represents an increase of 1% from last year’s total and continues a decade-long trend that has positioned Northwestern among the nation’s most prestigious research institutions. Since 2011, the University’s research funding has increased more than 74% as Northwestern approaches $1 billion in sponsored support, a feat achieved by only its top academic peers.
“Our research portfolio now includes a higher percentage of larger, complex awards, reflecting the collaborative approach to research that Northwestern fosters,” said Shandra White, executive director of Sponsored Research. “Having diverse projects within Northwestern’s research landscape is vital, along with the robust infrastructure to support the complexity of those high-impact investigations.”
|
|
Vetter: Insights on Injectable Drug Delivery |
|
Parenteral products represent a major growth engine in today’s surging global biopharma market. Their share of the global market figures to grow from 53% in 2020 ($606bn) to 57% in 2027 ($1,298bn), outpacing other routes of administration. On average, more than 40% of the medications approved by the FDA are injectable, with subcutaneous and intramuscular products making up a growing percentage of those approvals.
As more and more injectables enter the global pipeline, these new assets are facing major shifts in market expectations and lifecycle success factors. In today’s market, it takes far more than a promising molecule and a validated therapeutic target for new products to gain traction. Differentiating user experience, patient-centric features, and other commercial success factors are now as critical as the drug substance and its mechanism of action—not to mention the injectable delivery system that will be used to administer that new treatment. .
|
|
"Patient-centricity will be critical to the next generation of injectable products. For many users, the delivery experience is will be as important as the drug." noted Peter Soelkner, Vetter Managing Director
|
|
Biotech in Europe: Driving the Next Act |
|
Europe’s biotech industry continues on a trajectory of growth fueled by innovations from cell and gene therapies to antisense, messenger RNA (mRNA), and chimeric antigen receptor T-cell therapy (CAR-T), with more emerging technologies and techniques on the horizon. The industry has made considerable progress in improving access to capital and talent gaps in the past few years. However, its future growth will depend on whether it can continue to scale up innovation and keep up with the pace of change in other regions. Biotechs, investors, and other stakeholders will need to play their part in the industry’s next act if the promise of a golden age of biotech is to become a reality. |
|
Biotechs and investors seeking to build companies that achieve scale and success at bringing innovative assets to market should go global. Be open to following talent, money, and opportunities beyond your home country and region. Go East or West, particularly to the United States and China, to build a global organization, global networks, and global credibility. To read the entire article, click here.
|
|
LanzaTech: C-Suite Recognition |
|
Holmgren responded to a number of questions. As a preview, one of the questions was. What’s the coolest thing about your industry?
Holmgren's response: "We are converting pollution into fabric for Lululemon, perfume for Coty, laundry detergent and sustainable aviation fuel so we don’t have to dig fresh carbon out of the ground. I’m not going to sleep well until we do more. The whole world is on fire, and we need to move faster to solve our pollution problem." To read the entire Crain's article, click here.
|
|
WIB-Chicago: Start-up Challenge 7.0 |
|
Join WIB-Chicago for its seventh annual Start-up Challenge to see finalists from women-led Midwest biotech companies pitch their technology and products. Local experts from the investment and start-up communities will provide feedback and select the winning pitch, with the winner receiving a cash prize. Companies selected to be finalists will each receive an annual WIB Membership, an opportunity to connect with industry leaders, and an exclusive network of women founders.
|
|
Cyclopure DEXSORB Absorbent Update |
|
Cyclopure continues to move its NSF 61-certified DEXSORB® adsorbent forward for use in environmental applications for the removal of PFAS from water supplies. The company has recently signed on to several new pilot installations for groundwater remediation and the treatment of wastewater effluent and drinking water supplies, with two deployments planned for the fourth quarter of 2021.
Cyclopure's skid-mounted pilot systems, in a lead-lag vessel configuration, will provide full-scale demonstration of PFAS removal performance. Pilot activities will also encompass full treatment train capabilities of spent media regeneration and destruction of the isolated PFAS waste stream. For more about Cyclopure, click here.
|
|
ISTP and Alveole Honey Harvesting Buzz |
|
Urban beekeeping brings people together around an awe-inspiring experience through interactive, thought-provoking conferences and activities that allow for deeper conversations about sustainability.
This sustainable solution inspires people and organizations to do better and do more for the environment, with the added benefit of producing ultra local urban honey – a sweet tool for our community. .
Participants from Northshore, Charles River, LanzaTech and American Landmark learned about urban beekeeping and the little city that is a beehive. They also help harvest the honey that the bees have been making at ISTP. To learn more about Alveole, click here.
|
|
Ever alert to new opportunities, contract development and manufacturing organizations (CDMOs) are well aware that cell and gene therapies are generating excitement among industry analysts. For example, Deloitte recently predicted that the cell and gene therapy market will generate revenues of $12 billion a year by 2025, which is an impressive jump for a market valued at just $1 billion three years ago. Deloitte indicated that its prediction was based on the high level of activity in cell and gene therapy R&D—more than 1,000 clinical trials were ongoing in 2019—and the large number of developers entering the space.
Charles River Laboratories (CRL), long known as a research services firm, says that it is expanding its manufacturing business while pursuing a “technology agnostic” strategy that emphasizes innovation and flexibility. To read the entire article, click here.
|
|
Says Mike Austin, corporate vice president, Global Operations Cell and Gene Therapy CDMO Services, CRL. "Our combined capabilities allow clients to bring their cell and gene therapies from early research and discovery all the way through commercialization in a single, streamlined program.” |
|
NU Accelerator to Support Startups |
|
Northwestern will create an accelerator in downtown Evanston to support the development of faculty-led startups in health-related fields with laboratory space and resource access.
The project, which will be located at 1801 Maple Ave., has already secured at least $75 million in funding for research and business development, $50 million of which will come from the Illinois General Assembly in its 2022 budget. Kimberly Querrey, chair of the Innovation and Entrepreneurship Committee of NU’s Board of Trustees, also put forth a $25 million donation to the accelerator, which will be named in her honor.
The existing location will be renovated to include both laboratory and office space, providing opportunities for further research and entrepreneurial efforts — both of which have been highly prioritized by the University, resulting in global recognition. According to the University release, it will also create chances for economic growth for the Evanston, Skokie and Chicago communities.
|
|
“This effort will expand on Northwestern’s rich tradition of innovation and entrepreneurship by providing researchers with a launching pad for new ventures,” Querrey said in the release. “This space will benefit the entire University community, the local community and beyond, and it is extremely exciting to see it take shape.”
Northwestern President Morton Schapiro said in a statement that the accelerator will "shine a spotlight on our cutting-edge research and innovation and help the University recruit top talent. For the announcement, click here.
|
|
Check out Skokie and ISTP |
|
Living a CarbonSmart Life |
|
|
|
|
|
|
